REMARKS

A. Claim Amendments

For clarity, Claim 2 has been amended to specify that the proteins whose cleavage into soluble form is referenced (TNFα and TNFα lacking the TACE metalloproteinase recognition site spanning the valine 77 to the proline 88 of TNFα) are human TNFα, as described in, for example, paragraphs 0008 and 0082, and referenced in the experiments described at paragraphs 0111 to 0113, and Figures 3 through 5. Extraneous hyphens in the cell line names recited in Claim 2 have also been deleted.

No new matter has been added to the application by the amendment and newly added claims, entry of which is therefore respectfully requested.

B. Response to Rejection of Claims 2-4, 8, 11-12, 27-29, 32-41, 68 and 76-79 under 35 USC 112, First Paragraph (written description).

The listed claims are rejected on the basis that the Specification lacks essential matter in not reciting the entire amino acid sequence of the deleted mmp recognition site and/or the amino acid sequence of TNFα. To the extent that the rejection requires more clarity about the identity of the particular TNFα containing the recognition sequence recited as a reference in Claim 2, the present amendment to the claim provides it. In particular, it is now specified that the reference is to *human* TNFα molecules and that the putatively deleted sequence is the entire "TACE mmp recognition sequence" spanning from Val77 to Pro88 in human TNFα.

The amino acid sequences for human TNFα and the Val77 to Pro88 span were well known prior to the filing of the patent application. The molecules are clearly described in the Specification to an extent allowing one of ordinary skill in the art to readily and unambiguously identify them. For example, the reference molecules which produce more soluble TNFα than the chimeric molecules of the invention are described in the Specification as human pro-TNFα lacking a

specified mmp recognition sequence (for the TACE mmp) and human TNFα at, for example, paragraphs 0007 and 0008, which read:

> "There are two bioactive forms of TNF.alpha.. One form is membrane-integrated (mTNF.alpha.), also referred to as pro-TNF.alpha... [*paragraph 0007*].
>
> A matrix metalloproteinase (mmp) called TACE (for TNF-alpha converting enzyme) has been shown to release the soluble form of TNF.alpha. (Black et al, Nature, 385:729-733, 1997 and Moss et al, Nature, 385:733-736, 1997). TACE has been found to release sTNF.alpha. by cleaving pro-TNF.alpha. between amino acid residues alanine76 and valine77. Moreover, this cleavage is dependent on an approximately **12 amino acid mmp recognition sequence spanning valine77 to proline88** (Decoster et al, J Biol Chem, 270:18473-18478, 1995 and Tang et al, Biochemistry, 35:8226-8233, 1996) since deletion of 9 to 12 amino acids of this mmp recognition site inhibited the cleavage of the parent TNF.alpha. molecule (Decoster et al, J Biol Chem, 270:18473-18478, 1995 and Perez et al, Cell, 63:251-258, 1990). However, deletion of this cleavage site does not necessarily completely abrogate sTNF.alpha. generation due to the existence of multiple cleavage sites in TNF.alpha. (Mueller et al, J Biol Chem, 274:38112-38118, 1999)." [*paragraph 0008, emphasis added*].

The amino acid sequence of TNFα has been known to the art since the early 1990s, including the "12 amino acid mmp recognition sequence spanning valine77 to proline88" as taught above and now recited in Claim 2. There is no question that one of ordinary skill in the art would know, or could readily obtain, the structure of the recited polypeptides with very little effort—consulting the published art referenced in the patent application would do it, as would a quick search of any protein database, such as the protein bank on the National Institutes of Health's PubMed, which includes the amino acid sequence for human TNFα as NP_000585.2 (see, enclosed Attachment A).

The complete sequence of TNFα and the TACE recognition site are therefore not essential matter which must be disclosed in the Specification to fully describe the invention and enable the art to practice it. To the contrary, it is axiomatic that one need not disclose details of structures which are well-known in the art to meet the requirements of Section 112, first paragraph (see, e.g., *Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1385, 231 USPQ 81, 94 (Fed.Cir.1986) ("a patent need not teach, and preferably omits, that which is known in the art)).

Reconsideration and withdrawal of the Section 112, first paragraph (written description) rejection of the claims is therefore respectfully requested.

C. Response to Rejection of Claims 2-4, 8, 11-12, 27-29, 32-41, 68 and 76-79 under 35 USC 112, First Paragraph (written description).

The listed claims are rejected on the basis that the HeLa, 293, A549, COLO205, HCT-15, BT-20 and HT1080 cells/cell lines must be known to and readily available to the public or deposited.

The cells recited are extremely common tools used in cancer research, with many of them being publicly available since the 1950s, and all being commercially available since well prior to the filing date of the instant application (see, for example, Attachment B, pages from the American Type Culture Collection's cell line catalog listing for sale: HeLa cells as ATCC CCL-2, 293 cells as CCL-1573, HT 1080 cells as CCL-121, A549 cells as CCL-185, COLO 205 cells as CCL-222, HCT 15 cells as CCL-225, and BT 20 cells as HTB-19). One of ordinary skill in the art would immediately recognize the references in the claims to these cell lines and would either be likely to already have them on hand, or be able to readily obtain them.

Reconsideration and withdrawal of the Section 112, first paragraph (written description) rejection of the claims is therefore respectfully requested.

D. Supplemental Response to the Double-Patenting Rejections

Claims 2-4, 8, 11-12, 27-29, 32-41, 68, and 76-79 are objected to on the basis that "Applicant's amendment, filed 7/31/2009, does not address the issue of commonly owned at the time the invention was made." In response, it is confirmed as follows:

As to commonly assigned USSN 11/015,117 (now US Pat. No. 7524944), the invention claimed therein was made after the invention presently claimed. At that time, and at all times since, the invention of the '944 Patent and the presently claimed invention have been assigned to and/or subject to an obligation on the part of all inventors to assign to the present Assignee, the Regents of the University of California (see, confirmatory assignments recorded at reel/ frame 021549/0140 ['944 Patent] and reel/frame 012962/0392 [present application]).

As to commonly assigned US Pat. No. 7070771, the invention claimed therein was made prior to the invention presently claimed. At that time, and at all times since, the invention of the '771 Patent and the presently claimed invention have been assigned to and/or subject to an obligation on the part of all inventors to assign to the present Assignee, the Regents of the University of California (see, confirmatory assignments recorded at reel/ frame 0158921 ['771 Patent] and reel/frame 012962/0392 [present application]).

Statements under 37 CFR Section 3.73(b) confirming the above chains of title are already of record in the previously submitted and recorded terminal disclaimers viz the '944 and '771 Patents.

Reconsideration of the common ownership objection is therefore respectfully requested.

CONCLUSION

Applicants believe that the present application is now in condition for allowance. Favorable consideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

No fee is deemed necessary in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any other fees that may be due in connection with the filing of this paper, or credit any overpayment to Deposit Account No. 07-1896.

Respectfully submitted,

Date: March 1, 2010



Stacy L. Taylor
Registration No. 34,842
Telephone: (858) 677-1423
Facsimile: (858) 677-1465

DLA PIPER LLP (US)
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer Number 28213

Attachments:
Attachment A (Pages from the National Institutes of Health's PubMed protein bank)
Attachment B (Pages from the American Type Culture Collection's cell line catalog)

Attachment A

NCBI

All Databases PubMed Nucleotide Protein Genome Structure OMIM PM

Search Protein for Go Clear

Limits Preview/Index History Clipboard Details

Format: GenPept FASTA Graphics More Formats▼ Download▼ Save▼ L

NCBI Reference Sequence: NP_000585.2

tumor necrosis factor alpha [Homo sapiens]

Comment Features Sequence

LOCUS NP_000585 233 aa linear PRI 07-FEB-2010
DEFINITION tumor necrosis factor alpha [Homo sapiens].
ACCESSION NP_000585
VERSION NP_000585.2 GI:25952111
DBSOURCE REFSEQ: accession NM_000594.2
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
REFERENCE 1 (residues 1 to 233)
AUTHORS Skibola,C.F., Bracci,P.M., Nieters,A., Brooks-Wilson,A., de
Sanjose,S., Hughes,A.M., Cerhan,J.R., Skibola,D.R., Purdue,M.,
Kane,E., Lan,Q., Foretova,L., Schenk,M., Spinelli,J.J., Slager,S.L., De Roos,A.J., Smith,M.T., Roman,E., Cozen,W., Boffetta,P., Kricker,A., Zheng,T., Lightfoot,T., Cocco,P., Benavente,Y., Zhang,Y., Hartge,P., Linet,M.S., Becker,N., Brennan,P., Zhang,L., Armstrong,B., Smith,A., Shiao,R., Novak,A.J.,
Maynadie,M., Chanock,S.J., Staines,A., Holford,T.R., Holly,E.A.,
Rothman,N. and Wang,S.S.
TITLE Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph
Consortium
JOURNAL Am. J. Epidemiol. 171 (3), 267-276 (2010)
PUBMED 20047977
REMARK GeneRIF: Meta-analysis of gene-disease association. (HuGE Navigator)
REFERENCE 2 (residues 1 to 233)
AUTHORS La Manna,G., Cappuccilli,M.L., Cianciolo,G., Conte,D., Comai,G.,
Carretta,E., Scolari,M.P. and Stefoni,S.
TITLE Cardiovascular Disease in Kidney Transplant Recipients: The
Prognostic Value of Inflammatory Cytokine Genotypes

Change Regio

Customize Vie

Analyze This S

Run BLAST

Identify Conse

Articles about t

TNFalpha -30
is [illegible]

Association of factor alpha g

Association of factor alpha [illegible]

Identical Protei

tumor necrosi

unnamed prot

tumor necrosi

Pathways for th gene

NOD-like rece pathway

Dilated cardio

RIG-I-like rece pathway

Genomic RefS

See the genomic for the TNF gene

RefSeq mRNA

JOURNAL Transplantation (2010) In press
PUBMED 20061995
REMARK GeneRIF: Observational study of gene-disease association. (HuGE Navigator)
Publication Status: Available-Online prior to print
REFERENCE 3 (residues 1 to 233)
AUTHORS Welsby,I.J., Podgoreanu,M.V., Phillips-Bute,B., Morris,R., Mathew,J.P., Smith,P.K., Newman,M.F., Schwinn,D.A. and Stafford-Smith,M.
CONSRTM Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team
TITLE Association of the 98T ELAM-1 Polymorphism with Increased Bleeding After Cardiac Surgery
JOURNAL J. Cardiothorac. Vasc. Anesth. (2010) In press
PUBMED 20056442
REMARK GeneRIF: Observational study of gene-disease association. (HuGE Navigator)
Publication Status: Available-Online prior to print
REFERENCE 4 (residues 1 to 233)
AUTHORS Ghosh,J., Joshi,G., Pradhan,S. and Mittal,B.
TITLE Investigation of TNFA 308G > A and TNFB 252G > A polymorphisms in genetic susceptibility to migraine
JOURNAL J. Neurol. (2009) In press
PUBMED 20035431
REMARK GeneRIF: Observational study of gene-disease association. (HuGE Navigator)
Publication Status: Available-Online prior to print
REFERENCE 5 (residues 1 to 233)
AUTHORS Menegatti,E., Davit,A., Francica,S., Berardi,D., Rossi,D., Baldovino,S., Tovo,P.A., Sena,L.M. and Roccatello,D.
TITLE Genetic factors associated with rheumatoid arthritis and systemic vasculitis: Evaluation of a panel of polymorphisms
JOURNAL Dis. Markers 27 (5), 217-223 (2009)
PUBMED 20037209
REMARK GeneRIF: Observational study of gene-disease association. (HuGE Navigator)
REFERENCE 6 (sites)
AUTHORS Mohan,M.J., Seaton,T., Mitchell,J., Howe,A., Blackburn,K., Burkhart,W., Moyer,M., Patel,I., Waitt,G.M., Becherer,J.D., Moss,M.L. and Milla,M.E.
TITLE The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity
JOURNAL Biochemistry 41 (30), 9462-9469 (2002)
PUBMED 12135369
REMARK Erratum:[Biochemistry. 2003 Sep 23;42(37):11092]
REFERENCE 7 (sites)
AUTHORS English,W.R., Puente,X.S., Freije,J.M., Knauper,V., Amour,A., Merryweather,A., Lopez-Otin,C. and Murphy,G.
TITLE Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis

See reference m
the TNF gene (N

More about th

This gene encod
proinflammatory
belongs to the tu
(TNF) superfamil
m...
Also Known As: I
TNF-a...

Homologs of t

The TNF gene is
chimpanzee, dog
rat.

Recent activi

TNF (11
tumor ne
[Homo s
homo sa
(120)
TNFalph
homo sa
alpha (7

All links from

BLink
Related sequ
Identical prot
BioAssay by
BioAssay by
sequence
BioSystems
Conserved d
Domain relat
Full text in PI
Gene
Gene genoty
GeneView in

factor-alpha convertase activity but does not activate pro-MMP2
JOURNAL J. Biol. Chem. 275 (19), 14046-14055 (2000)
PUBMED 10799478
REFERENCE 8 (sites)
AUTHORS Roghani,M., Becherer,J.D., Moss,M.L., Atherton,R.E., Erdjument-Bromage,H., Arribas,J., Blackburn,R.K., Weskamp,G., Tempst,P. and Blobel,C.P.
TITLE Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity
JOURNAL J. Biol. Chem. 274 (6), 3531-3540 (1999)
PUBMED 9920899
REFERENCE 9 (sites)
AUTHORS Pocsik,E., Duda,E. and Wallach,D.
TITLE Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells
JOURNAL J. Inflamm. 45 (3), 152-160 (1995)
PUBMED 8597870
REFERENCE 10 (residues 1 to 233)
AUTHORS Buonaguro,L., Barillari,G., Chang,H.K., Bohan,C.A., Kao,V., Morgan,R., Gallo,R.C. and Ensoli,B.
TITLE Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines
JOURNAL J. Virol. 66 (12), 7159-7167 (1992)
PUBMED 1279199
REFERENCE 11 (residues 1 to 233)
AUTHORS Zhang,X.M., Weber,I. and Chen,M.J.
TITLE Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship
JOURNAL J. Biol. Chem. 267 (33), 24069-24075 (1992)
PUBMED 1331108
REFERENCE 12 (residues 1 to 233)
AUTHORS Stevenson,F.T., Bursten,S.L., Locksley,R.M. and Lovett,D.H.
TITLE Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues
JOURNAL J. Exp. Med. 176 (4), 1053-1062 (1992)
PUBMED 1402651
REFERENCE 13 (sites)
AUTHORS Stevenson,F.T., Bursten,S.L., Locksley,R.M. and Lovett,D.H.
TITLE Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues
JOURNAL J. Exp. Med. 176 (4), 1053-1062 (1992)
PUBMED 1402651
REFERENCE 14 (residues 1 to 233)
AUTHORS Spriggs,D.R., Deutsch,S. and Kufe,D.W.
TITLE Genomic structure, induction, and production of TNF-alpha
JOURNAL Immunol. Ser. 56, 3-34 (1992)
PUBMED 1550865
REMARK Review article
REFERENCE 15 (residues 1 to 233)
AUTHORS Pryke,A.M., Duggan,C., White,C.P., Posen,S. and Mason,R.S.
TITLE Tumor necrosis factor-alpha induces vitamin D-1-hydroxylase activity in normal human alveolar macrophages
JOURNAL J. Cell. Physiol. 142 (3), 652-656 (1990)
PUBMED 1690216
COMMENT REVIEWED REFSEQ: This record has been curated by NCBI staff. The

Genome
Genome proj
HomoloGene
Map viewer
Nucleotide
OMIM
Protein (UniF
PubMed
PubMed (Ref
PubMed (wei
Related struc
SNP
Taxonomy
UniGene
LinkOut

reference sequence was derived from M10988.1 and BI908079.1.
On Nov 29, 2002 this sequence version replaced gi:10835155.

Summary: This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. [provided by RefSeq].

Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Entrez Gene record to access additional publications.

FEATURES Location/Qualifiers

source 1..233
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"

Protein 1..233
/product="tumor necrosis factor alpha"
/note="cachectin; TNF superfamily, member 2; TNF, monocyte-derived; TNF, macrophage-derived; APC1 protein"
/calculated_mol_wt=25513

Site 2
/site_type="phosphorylation"
/experiment="experimental evidence, no additional details recorded"
/citation=[9]
/db_xref="HPRD:15110"

Site 19
/site_type="myristoylation"
/experiment="experimental evidence, no additional details recorded"
/citation=[12]

Site 20
/site_type="myristoylation"
/experiment="experimental evidence, no additional details recorded"
/citation=[12]

Site 74
/site_type="modified"
/experiment="experimental evidence, no additional details recorded"
/note="proteolytic cleavage site"
/citation=[7]
/db_xref="HPRD:03793"

Site 74
/site_type="modified"
/experiment="experimental evidence, no additional details recorded"
/note="proteolytic cleavage site"
/citation=[8]
/db_xref="HPRD:04091"

Site 74
/site_type="modified"

```
                     /experiment="experimental evidence, no additional details
                     recorded"
                     /note="proteolytic cleavage site"
                     /citation=[7]
                     /db_xref="HPRD:04703"
     Site            76
                     /site_type="modified"
                     /experiment="experimental evidence, no additional details
                     recorded"
                     /note="proteolytic cleavage site"
                     /citation=[6]
                     /citation=[7]
                     /db_xref="HPRD:04703"
     Site            76
                     /site_type="modified"
                     /experiment="experimental evidence, no additional details
                     recorded"
                     /note="proteolytic cleavage site"
                     /citation=[8]
                     /db_xref="HPRD:04091"
     Site            79
                     /site_type="modified"
                     /experiment="experimental evidence, no additional details
                     recorded"
                     /note="proteolytic cleavage site"
                     /citation=[8]
                     /db_xref="HPRD:04091"
     Region          88..231
                     /region_name="TNF"
                     /note="Tumor Necrosis Factor; TNF superfamily members
                     include the cytokines: TNF (TNF-alpha), LT
                     (lymphotoxin-alpha, TNF-beta), CD40 ligand, Apo2L (TRAIL),
                     Fas ligand, and osteoprotegerin (OPG) ligand. These
                     proteins generally have an intracellular N-terminal...;
                     cd00184"
                     /db_xref="CDD:29146"
     Site            order(91,133,135,195,200,227,231)
                     /site_type="other"
                     /note="trimer interface"
                     /db_xref="CDD:29146"
     Site            order(105..106,111,153,160,165)
                     /site_type="other"
                     /note="receptor binding sites"
                     /db_xref="CDD:29146"
     CDS             1..233
                     /gene="TNF"
                     /gene_synonym="DIF; TNF-alpha; TNFA; TNFSF2"
                     /coded_by="NM_000594.2:170..871"
                     /db_xref="CCDS:CCDS4702.1"
                     /db_xref="GeneID:7124"
                     /db_xref="HGNC:11892"
                     /db_xref="HPRD:01855"
                     /db_xref="MIM:191160"
ORIGIN
        1 mstesmirdv elaeealpkk tggpqgsrrc lflslfsfli vagattlfcl lhfgvigpqr
       61 eefprdlsli splaqavrss srtpsdkpva hvvanpqaeg qlqwlnrran allangvelr
      121 dnqlvvpseg lyliysqvlf kgqgcpsthv llthtisria vsyqtkvnll saikspcqre
      181 tpegaeakpw yepiylggvf qlekgdrlsa einrpdyldf aesgqvyfgi ial
//
```

Attachment B

ATCC
The Global Bioresource Center™

Search Catalo
Select a Category

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfe certain cases, an MTA specified by the depositing institution.
Customers in Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Macau, Mexico, New Zealanc Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and pr

Cell Biology

ATCC® Number:	**CCL-121™** Order this Item	**Price:**	**$272.00**
Designations:	HT-1080		**Related I**
Biosafety Level:	1		NCBI Entrez
Shipped:	frozen		Make a Dep
Medium & Serum:	See Propagation		Frequently /
Growth Properties:	adherent		Material Tra
Organism:	*Homo sapiens* (human)		Technical Si
Morphology:	epithelial		Related Cell
Source:	**Tissue:** connective tissue **Disease:** fibrosarcoma		
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.		
Isolation:	**Isolation date:** July, 1972		
Applications:	transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents)		
Virus Susceptibility:	Human poliovirus 1 RD-114 Feline Feline leukemia virus Vesicular stomatitis virus		
Tumorigenic:	Yes		
Reverse Transcript:	negative		
Oncogene:	ras +		

DNA Profile (STR):	Amelogenin: X,Y CSF1PO: 12 D13S317: 12,14 D16S539: 9,12 D5S818: 11,13 D7S820: 9,10 THO1: 6 TPOX: 8 vWA: 14,19
Cytogenetic Analysis:	modal number = 46; range = 44 to 48. Pseudodiploidy was frequently noted. About 40% of the cells had rearranged karyotypes with an extra E-group chromosome and a group C chromosome, probably chromosome 11, was missing.
Isoenzymes:	G6PD, B
Age:	35 years
Gender:	male
Ethnicity:	Caucasian
Comments:	The cells contain an activated N-ras oncogene.
Propagation:	**ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. **Temperature:** 37.0°C
Subculturing:	**Protocol:**

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
   Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. Add appropriate aliquots of the cell suspension to new culture vessels.
6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days

Preservation:	**Freeze medium:** Complete growth medium supplemented with 5% (v/v) DMSO **Storage temperature:** liquid nitrogen vapor phase
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003 recommended serum:ATCC 30-2020

References:

22147: Chen TR, et al. Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. Cancer Genet. Cytogenet. 10: 351-362, 1983. PubMed: 6652615
23071: Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289
23393: Rasheed S, et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33: 1027-1033, 1974. PubMed: 4132053
25969: Adams RA, et al. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2. Cancer Res. 28: 1121-1125, 1968. PubMed: 4872716
26035: . . Proc. Am. Assoc. Cancer Res. 8: 1, 1967.
32289: Hu M, et al. Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin. Cancer Res. 57: 3577-3584, 1997. PubMed: 9270031
32370: Iida A, et al. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J. Virol. 70: 6054-6059, 1996. PubMed: 8709228
32531: Brenneman M, et al. Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific endonucleases. Proc. Natl. Acad. Sci. USA 93: 3608-3612, 1996. PubMed: 8622983
33061: Seiffert D. Hydrolysis of platelet vitronectin by calpain. J. Biol. Chem. 271: 11170-11176, 1996. PubMed: 8626663
33152: Hocking AM, et al. Eukaryotic expression of recombinant biglycan. J. Biol. Chem. 271: 19571-19577, 1996. PubMed: 8702651

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only, unless noted otherwise. They are not intended fo

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warr representations as to its accuracy. Citations from scientific literature and patents are provided for informational purp not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will b cultures for nonprofit institutions in the United States. Cultures that are ordered as test tubes or flasks will carry an a fee. Fees for permits, shipping, and handling may apply.
Back to my Search

© 2009 ATCC. All Rights Reserved.

ATCC
The Global Bioresource Center™

Search Catalo
Select a Category

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfe certain cases, an MTA specified by the depositing institution.
Customers in Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Macau, Mexico, New Zealanc Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and pr

Cell Biology

ATCC® Number:	**CRL-1573™** Order this Item	**Price:**	**$256.00**
Designations:	293 [HEK-293]		**Related I**
Depositors:	FL Graham		NCBI Entrez
Biosafety Level:	2 [CELLS CONTAIN ADENOVIRUS]		Cell Microgr
Shipped:	frozen		Make a Dep
Medium & Serum:	See Propagation		Frequently /
Growth Properties:	adherent		Material Tra
Organism:	*Homo sapiens* (human)		Technical Si
Morphology:	epithelial		Related Cell
	PHOTO		
Source:	**Organ:** embryonic kidney **Cell Type:** transformed with adenovirus 5 DNA		
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.		
Restrictions:	These cells are distributed for research purposes only. 293 cells, their products, or their derivatives may not be distributed to third parties.		
Applications:	efficacy testing [92587] transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents) viruscide testing [92579]		
Receptors:	vitronectin, expressed		
Tumorigenic:	Yes		

DNA Profile (STR):	Amelogenin: X CSF1PO: 11,12 D13S317: 12,14 D16S539: 9,13 D5S818: 8,9 D7S820: 11,12 THO1: 7,9.3 TPOX: 11 vWA: 16,19
Cytogenetic Analysis:	This is a hypotriploid human cell line. The modal chromosome number was 64, occurring in 30% of cells. The rate of cells with higher ploidies was 4.2 %. The der(1)t(1;15) (q42;q13), der(19)t(3;19) (q12;q13), der(12)t (8;12) (q22;p13), and four other marker chromosomes were common to most cells. Five other markers occurred in some cells only. The marker der (1) and M8 (or Xq+) were often paired. There were four copies of N17 and N22. Noticeably in addition to three copies of X chromosomes, there were paired Xq+, and a single Xp+ in most cells.
Age:	fetus
Comments:	Although an earlier report suggested that the cells contained Adenovirus 5 DNA from both the right and left ends of the viral genome [RF32764], it is now clear that only left end sequences are present. [39768] The line is excellent for titrating human adenoviruses. The cells express an unusual cell surface receptor for vitronectin composed of the integrin beta-1 subunit and the vitronectin receptor alpha-v subunit. [23406] The Ad5 insert was cloned and sequenced, and it was determined that a colinear seqment from nts 1 to 4344 is integrated into chromosome 19 (19q13.2). [39768]
Propagation:	**ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. **Atmosphere:** air, 95%; carbon dioxide (CO2), 5% **Temperature:** 37.0°C The cell line does not adhere to the substrate when left at room temperature for any length of time, therefore, live cultures may be received with the cells detached.The cells will re-attach to the flask over a period of several days in culture at 37C.
Subculturing:	**Protocol:** 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. 3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. 4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. 5. Add appropriate aliquots of the cell suspension to new culture vessels.An inoculum of 2 X 10 (3) to 6 X 10 (3) viable cells/cm2 is recommended. 6. Incubate cultures at 37°C.6. Subculture when cell concentration is between 6 and 7 X 10(4) cells/cm2. **Subcultivation Ratio:** 1:10 to 1:20 weekly. **Medium Renewal:** Every 2 to 3 days
Preservation:	**Freeze medium:** Complete growth medium supplemented with 5% (v/v) DMSO **Storage temperature:** liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC 30-2003
derivative: ATCC CRL-10852
derivative: ATCC CRL-12006
derivative: ATCC CRL-12007
derivative: ATCC CRL-12013
derivative: ATCC CRL-12479
derivative: ATCC CRL-2029
derivative: ATCC CRL-2368
purified DNA:ATCC CRL-1573D

References:

21624: Xie QW, et al. Complementation analysis of mutants of nitric oxide synthase reveals that the active site requires two hemes. Proc. Natl. Acad. Sci. USA 93: 4891-4896, 1996. PubMed: 8643499
21631: Da Costa LT, et al. Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA 93: 4192-4196, 1996. PubMed: 8633039
22282: Graham FL, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59-72, 1977. PubMed: 886304
22319: Graham FL, et al. Defective transforming capacity of adenovirus type 5 host-range mutants. Virology 86: 10-21, 1978. PubMed: 664220
22699: Harrison T, et al. Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 77: 319-329, 1977. PubMed: 841862
23406: Bodary SC, McLean JW. The integrin beta 1 subunit associates with the vitronectin receptor alpha v subunit to form a novel vitronectin receptor in a human embryonic kidney cell line. J. Biol. Chem. 265: 5938-5941, 1990. PubMed: 1690718
27819: Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71: 548-561, 1997. PubMed: 8985383
28301: Loffler S, et al. CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J. Virol. 71: 42-49, 1997. PubMed: 8985321
32283: Hu SX, et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57: 3339-3343, 1997. PubMed: 9269991
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
32490: Stauderman KA, et al. Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha 2 beta 4, alpha 3 beta 4 and alpha 4 beta 4 stably expressed in HEK293 cells. J. Pharmacol. Exp. Ther. 284: 777-789, 1998. PubMed: 9454827
32514: Bartz SR, et al. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70: 2324-2331, 1996. PubMed: 8642659
32726: Sandri-Goldin RM, Hibbard MK. The herpes simplex virus type 1 regulatory protein ICP27 coimmunoprecipitates with anti-sm antiserum, and the C terminus appears to be required for this interaction. J. Virol. 70: 108-118, 1996. PubMed: 8523514
32829: Ansieau S, et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc. Natl. Acad. Sci. USA 93: 14053-14058, 1996. PubMed: 8943059
32893: Zhang J, et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. J. Biol. Chem. 271: 18302-18305, 1996. PubMed: 8702465
32914: Oppermann M, et al. Monoclonal antibodies reveal receptor specificity among G-protein-coupled receptor kinases. Proc. Natl. Acad. Sci. USA 93: 7649-7654, 1996. PubMed: 8755530
32921: Xia Y, et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl. Acad. Sci. USA 93: 6770-6774, 1996. PubMed: 8692893
32925: Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224
32971: Uebele VN, et al. Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kvbeta2.1 subunits. J. Biol. Chem. 271: 2406-2412, 1996. PubMed: 8576199
33003: Abell A, et al. Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor. J. Biol. Chem. 271: 4518-4527, 1996. PubMed: 8626807
33010: Tiberi M, et al. Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J. Biol.

Chem. 271: 3771-3778, 1996. PubMed: 8631993
33022: Shahrestanifar M, et al. Studies on inhibition of mu and delta opioid receptor binding by dithiothreitol and N-ethylmaleimide. His223 is critical for mu opioid receptor binding and inactivation by N-ethylmaleimide. J. Biol. Chem. 271: 5505-5512, 1996. PubMed: 8621408
33035: Boring L, et al. Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein 1alpha receptors. J. Biol. Chem. 271: 7551-7558, 1996. PubMed: 8631787
33036: Noonberg SB, et al. Evidence of post-transcriptional regulation of U6 small nuclear RNA. J. Biol. Chem. 271: 10477-10481, 1996. PubMed: 8631843
33050: Fox JC, Shanley JR. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells. J. Biol. Chem. 271: 12578-12584, 1996. PubMed: 8647868
33056: Lee MJ, et al. The inducible G protein-coupled receptor edg-1 signals via the Gi/mitogen-activated protein kinase pathway. J. Biol. Chem. 271: 11272-11279, 1996. PubMed: 8626678
33123: Marchand P, et al. Cysteine mutations in the MAM domain result in monomeric meprin and alter stability and activity of the proteinase. J. Biol. Chem. 271: 24236-24241, 1996. PubMed: 8798668
33137: Arai H, Charo IF. Differential regulation of G-protein-mediated signaling by chemokine receptors. J. Biol. Chem. 271: 21814-21819, 1996. PubMed: 8702980
33138: Huang Q, et al. Substrate recognition by tissue factor-factor VIIa. J. Biol. Chem. 271: 21752-21757, 1996. PubMed: 8702971
33157: Monteclaro FS, Charo IF. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. J. Biol. Chem. 271: 19084-19092, 1996. PubMed: 8702581
33158: Keith DE, et al. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271: 19021-19024, 1996. PubMed: 8702570
39768: Louis N, et al. Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233: 423-429, 1997. PubMed: 9217065
61259: Shaw G, et al. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 16: 869-871, 2002. PubMed: 11967234
92579: Standard Test Method for Determining the Virus-Eliminating Effectiveness of Liquid Hygienic Handwash and Handrub Agents Using the Fingerpads of Adult Volunteers. West Conshohocken, PA:ASTM International;ASTM Standard Test Method E 1838-02.
92587: Standard Quantitative Disk Carrier Test Method for Determining the Bactericidal, Virucidal, Fungicidal, Mycobactericidal and Sporicidal Activities of Liquid Chemical Germicides. West Conshohocken, PA:ASTM International;ASTM Standard Test Method E 2197-02.

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only, unless noted otherwise. They are not intended fo

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warr representations as to its accuracy. Citations from scientific literature and patents are provided for informational purp not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will b cultures for nonprofit institutions in the United States. Cultures that are ordered as test tubes or flasks will carry an a fee. Fees for permits, shipping, and handling may apply.
Back to my Search

© 2009 ATCC. All Rights Reserved.

ATCC
The Global Bioresource Center™

Search Catalo
Select a Category

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfe certain cases, an MTA specified by the depositing institution.
Customers in Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Macau, Mexico, New Zealanc Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and pr

Cell Biology

ATCC® Number:	**CCL-185™** Order this Item	**Price:**	**$256.00**
Designations:	A549		**Related I**
Depositors:	M Lieber		NCBI Entrez
Biosafety Level:	1		Cell Microgr
Shipped:	frozen		Make a Dep
Medium & Serum:	See Propagation		Frequently /
Growth Properties:	adherent		Material Tra
Organism:	*Homo sapiens* (human)		Technical Si
Morphology:	epithelial		Related Cell
	PHOTO		
Source:	**Organ:** lung **Disease:** carcinoma		
Cellular Products:	keratin		
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.		
Isolation:	**Isolation date:** 1972		
Applications:	transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents)		
Reverse Transcript:	negative		
DNA Profile (STR):	Amelogenin: X,Y CSF1PO: 10,12 D13S317: 11 D16S539: 11,12 D5S818: 11 D7S820: 8,11 THO1: 8,9.3 TPOX: 8,11 vWA: 14		

Cytogenetic Analysis: This is a hypotriploid human cell line with the modal chromosome number of 66, occurring in 24% of cells. Cells with 64 (22%), 65, and 67 chromosome counts also occurred at relatively high frequencies; the rate with higher ploidies was low at 0.4%. There were 6 markers present in single copies in all cells. They include der(6)t(1;6) (q11;q27); ?del(6) (p23); del(11) (q21), del(2) (q11), M4 and M5. Most cells had two X and two Y chromosomes. However, one or both Y chromosomes were lost in 40% of 50 cells analyzed. Chromosomes N2 and N6 had single copies per cell; and N12 and N17 usually had 4 copies.

Isoenzymes: G6PD, B

Age: 58 years

Gender: male

Ethnicity: Caucasian

Comments: This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male. [23218]
Further studies by M. Lieber, et al. revealed that A549 cells could synthesize lecithin with a high percentage of desaturated fatty acids utilizing the cytidine diphosphocholine pathway. [58030]
The cells are positive for keratin by immunoperoxidase staining.

Propagation: **ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated F-12K Medium, Catalog No. 30-2004. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C

Subculturing: **Protocol:**

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
   Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. Add appropriate aliquots of the cell suspension to new culture vessels.
   Cultures can be established between 2 X 10(3) and 1 X 10(4) viable cells/cm2. Do not exceed 7 X 10(4) cels/cm2.
6. Incubate cultures at 37°C.

Interval: Maintain cultures at a cell concentration between 6 X 10(3) and 6 X 10(4) cell/cm2.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
Medium Renewal: 2 to 3 times per week

Preservation: **Freeze medium:** Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase

Doubling Time: about 22 hours

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2004
recommended serum:ATCC 30-2020

References:

23218: Giard DJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51: 1417-1423, 1973. PubMed: 4357758
27669: Mayr GA, Freimuth P. A single locus on human chromosome 21 directs the expression of a receptor for adenovirus type 2 in mouse A9 cells. J. Virol. 71: 412-418, 1997. PubMed: 8985365
27819: Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J. Virol. 71: 548-561, 1997. PubMed: 8985383
32299: St. Geme JW, et al. Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. J. Bacteriol. 178: 6281-6287, 1996. PubMed: 8892830
32347: Horikami SM, et al. The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication. Virology 222: 383-390, 1996. PubMed: 8806522
32351: Huang S, et al. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J. Virol. 70: 4502-4508, 1996. PubMed: 8676475
32373: Goodrum FD, et al. Adenovirus early region 4 34-kilodalton protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells. J. Virol. 70: 6323-6335, 1996. PubMed: 8709260
32394: Fang R, Aust AE. Induction of ferritin synthesis in human lung epithelial cells treated with crocidolite asbestos. Arch. Biochem. Biophys. 340: 369-375, 1997. PubMed: 9143343
32488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241
32496: Evdokiou A, Cowled PA. Tumor-suppressive activity of the growth arrest-specific gene GAS1 in human tumor cell lines. Int. J. Cancer 75: 568-577, 1998. PubMed: 9466658
32511: Giavedoni LD, Yilma T. Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon. J. Virol. 70: 2247-2251, 1996. PubMed: 8642649
32514: Bartz SR, et al. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70: 2324-2331, 1996. PubMed: 8642659
32722: Garofalo R, et al. Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RelA transcription factor as a mechanism producing airway mucosal inflammation. J. Virol. 70: 8773-8781, 1996. PubMed: 8971006
32758: Jamaluddin M, et al. Inducible translational regulation of the NF-IL6 transcription factor by respiratory syncytial virus infection in pulmonary epithelial cells. J. Virol. 70: 1554-1563, 1996. PubMed: 8627674
33091: Lewis JA, et al. Inhibition of mitochondrial function by interferon. J. Biol. Chem. 271: 13184-13190, 1996. PubMed: 8662694
58030: Lieber M, et al. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int. J. Cancer 17: 62-70, 1976. PubMed: 175022

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only, unless noted otherwise. They are not intended fo

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warr representations as to its accuracy. Citations from scientific literature and patents are provided for informational purp not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will b cultures for nonprofit institutions in the United States. Cultures that are ordered as test tubes or flasks will carry an a fee. Fees for permits, shipping, and handling may apply.
Back to my Search

ATCC®
The Global Bioresource Center™

Search Catalo
Select a Category

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfe
certain cases, an MTA specified by the depositing institution.
Customers in Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Macau, Mexico, New Zealanc
Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and pr

Cell Biology

ATCC® Number:	**CCL-225™** Order this Item	**Price:**	**$264.00**
Designations:	HCT-15		**Related I**
Depositors:	DL Dexter		NCBI Entrez
Biosafety Level:	1		Cell Microgr
Shipped:	frozen		Make a Dep
Medium & Serum:	See Propagation		Frequently /
Growth Properties:	adherent		Material Tra
Organism:	*Homo sapiens* (human)		Technical S
Morphology:	epithelial		Related Cell
	PHOTO		
Source:	**Organ:** colon **Tumor Stage:** Dukes' type C **Disease:** colorectal adenocarcinoma		
Cellular Products:	carcinoembryonic antigen (CEA) 5.4 ng/10 exp6 cells/10 days; keratin		
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.		
Applications:	transfection host (Roche FuGENE® Transfection Reagents)		
Tumorigenic:	Yes		
Reverse Transcript:	negative		

DNA Profile (STR):	Amelogenin: X,Y CSF1PO: 12 D13S317: 8,11 D16S539: 12,13 D5S818: 13 D7S820: 10,12 THO1: 7,9.3 TPOX: 8,11 vWA: 18,19
Cytogenetic Analysis:	This is a quasidiploid human cell line with the modal number 46 occurring in 76% of cells (range = 41 to 47 for 50 metaphases).The rate of polyploidy was 5.1%. The karyotype of the line 46, XY, -8,-11, -17, t (8:17)(p23:q21), inv(11)(p15.3q13.1). The Y chromosome was slightly longer than N22, and had a large segment of heterochromatic, fluorescent distal q arms.
Isoenzymes:	ES-D, 2 G6PD, B PEP-D, 1 PGD, A PGM1, 1-2 PGM3, 1
Gender:	male
Comments:	Evidence from DNA fingerprinting indicates that this line and DLD-1 (ATCC CCL-221) are derived from the same individual; however, isoenzymology and cytogenetic data leave some doubt. HCT-15 cells are CSAp negative (CSAp-). The cells are positive for keratin by immunoperoxidase staining.
Propagation:	**ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. **Temperature:** 37.0°C
Subculturing:	**Protocol:** 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. 3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. 4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. 5. Add appropriate aliquots of the cell suspension to new culture vessels. 6. Incubate cultures at 37°C. **Subcultivation Ratio:** A subcultivation ratio of 1:2 to 1:10 is recommended **Medium Renewal:** 2 to 3 times per week
Preservation:	**Freeze medium:** Complete growth medium, 95%; DMSO, 5% **Storage temperature:** liquid nitrogen vapor phase
Related Products:	Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020

References:

22417: Chen TR, et al. DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin. Cancer Genet. Cytogenet. 81: 103-108, 1995. PubMed: 7621404

22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287 -296, 1988. PubMed: 3338874

23033: Dexter DL, et al. N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res. 39: 1020-1025, 1979. PubMed: 427742

32266: Bender CM, et al. Inhibition of DNA methylation by 5-Aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58: 95-101, 1998. PubMed: 9426064

46971: Vermeulen SJ, et al. Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient?. Cancer Genet. Cytogenet. 107: 76-79, 1998. PubMed: 9809040

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only, unless noted otherwise. They are not intended fo

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warr representations as to its accuracy. Citations from scientific literature and patents are provided for informational purp not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will b cultures for nonprofit institutions in the United States. Cultures that are ordered as test tubes or flasks will carry an a fee. Fees for permits, shipping, and handling may apply.

Back to my Search

Login » To customize your ATCC web experience: Create a Profile

Home | Site Map | FAQ | Privacy Policy | Careers | Contact Us

© 2009 ATCC. All Rights Reserved.

Site Search

ATCC
The Global Bioresource Center™

Search Catalo
Select a Category

Product Description

Before submitting an order you will be asked to read and accept the terms and conditions of ATCC's Material Transfe
certain cases, an MTA specified by the depositing institution.
Customers in Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Macau, Mexico, New Zealanc
Taiwan, R.O.C. must contact a local distributor for pricing information and to place an order for ATCC cultures and pr

Cell Biology

ATCC® Number:	**HTB-19™** Order this Item	**Price:**	**$276.00**
Designations:	BT-20		**Related I**
Depositors:	EY Lasfargues		NCBI Entrez
Biosafety Level:	1		Make a Dep
Shipped:	frozen		Frequently /
Medium & Serum:	See Propagation		Material Tra
Growth Properties:	adherent		Technical S
Organism:	*Homo sapiens* (human)		Related Cell
Morphology:	epithelial		
Source:	**Organ:** mammary gland; breast **Disease:** carcinoma		
Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.		
Isolation:	**Isolation date:** 1958		
Tumorigenic:	Yes		
Reverse Transcript:	negative		
Antigen Expression:	HLA A1, Bw16 (+/-)		
DNA Profile (STR):	Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,14 D5S818: 12 D7S820: 10 THO1: 7,9.3 TPOX: 11 vWA: 16,17		

Cytogenetic Analysis: Normal chromosomes N3, N4, N9, N13, N14, and X may be absent. The markers der(11)t(11;?)(q25;?) (M1); der(1)t(1;3)(p22?;p13?) (M2); and der(2)t(2;?) (q37;?) (M5) were detected by W.A. Nelson-Rees, et al., Int. J. Cancer 16: 74-85, 1975.

Isoenzymes: AK-1, 1-2
ES-D, 1
G6PD, B
GLO-I, 1-2
PGM1, 1
PGM3, 1

Age: 74 years

Gender: female

Ethnicity: Caucasian

Comments: The cells express the WNT3 and the WNT7B oncogenes [PubMed: 8168088].
This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and cultivation of cells spilling out of the tumor when it was cut in thin slices. A mycoplasma contaminant was discovered and eliminated early in 1972.
Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha).
BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5.

Propagation: **ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C

Subculturing: **Protocol:**

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
   Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. Add appropriate aliquots of the cell suspension to new culture vessels.
6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: 2 to 3 times per week

Preservation: **Freeze medium:** Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020

References:

21405: Sugarman BJ, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. PubMed: 3933111
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
23079: Lan MS, et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res. 50: 2997-3001, 1990. PubMed: 2334903
23110: Castles CG, et al. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 53: 5934-5939, 1993. PubMed: 8261406
23113: Huguet EL, et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 54: 2615-2621, 1994. PubMed: 8168088
23212: Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J. Natl. Cancer Inst. 21: 1131-1147, 1958. PubMed: 13611537
23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
32275: Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764
32488: Geiger T, et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13: 35-45, 1998. PubMed: 9474241

Notices and Disclaimers

ATCC products are intended for laboratory research purposes only, unless noted otherwise. They are not intended fo

While ATCC uses reasonable efforts to include accurate and up-to-date information on this site, ATCC makes no warr representations as to its accuracy. Citations from scientific literature and patents are provided for informational purp not warrant that such information has been confirmed to be accurate.

All prices are listed in U.S. dollars and are subject to change without notice. A discount off the current list price will b cultures for nonprofit institutions in the United States. Cultures that are ordered as test tubes or flasks will carry an a fee. Fees for permits, shipping, and handling may apply.
Back to my Search

© 2009 ATCC. All Rights Reserved.